Fri, July 29, 2016
Thu, July 28, 2016
Wed, July 27, 2016

Matthew Harrison Maintained (VRTX) at Buy with Decreased Target to $139 on, Jul 28th, 2016

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $140 to $139 on, Jul 28th, 2016.

Matthew has made no other calls on VRTX in the last 4 months.



There is 1 other peer that has a rating on VRTX. Out of the 1 peers that are also analyzing VRTX, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Do Kim of "BMO Capital" Initiated at Hold on, Thursday, April 7th, 2016